Lisata Therapeutics, Inc. Board of Directors

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Mr. James Nisco

Mr. James Nisco

Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer

Dr. Kristen K. Buck M.D.

Dr. Kristen K. Buck M.D.

Executive VP of R&D and Chief Medical Officer

Mr. Tariq Imam

Mr. Tariq Imam

Vice President of Business Development & Operations and Corporate Counsel

Mr. John D. Menditto

Mr. John D. Menditto

Vice President of Investor Relations & Corporate Communications

Dr. William K. Sietsema Ph.D.

Dr. William K. Sietsema Ph.D.

Vice President of Global Regulatory Affairs

Mr. Gregory S. Berkin

Mr. Gregory S. Berkin

Chief Information & Data Protection Officer

Ms. Gail Holler

Ms. Gail Holler

Vice President of Human Resources

Comments